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Abstract 
Introduction and Background: Preeclampsia (PE), a hypertensive disorder specific to human 
pregnancy, remains a major cause of maternal mortality and morbidity globally. Endothelin-1 (ET-
1) is a powerful vasoconstrictor that plays a crucial role in endothelial cell dysfunction, a 
characteristic feature of preeclampsia development. As a result, this study assessed the role of ET-
1 in an HIV-infected preeclamptic cohort. Ethics approval was obtained BCA/17. 
Method: The study population (n = 72) was grouped according to pregnancy type i.e., 
normotensive (n = 36) and preeclamptic (n = 36) further stratified by human immunodeficiency 
virus (HIV) status. ET-1 levels were quantified using the Bioplex Immunoassay.  
Results: Gravidity, gestational age, systolic and diastolic blood pressure were significant across 
the study groups (p < 0.05). The concentration of ET-1 was significantly elevated in preeclamptic 
vs normotensive pregnancies regardless of HIV status (p ≤ 0.0418).  
Conclusion: This study observed a non-significant increase in ET-1 in the HIV positive pre-
eclampsia group compared to the HIV negative pre-eclampsia group. ET-1 was significantly 
increased in pre-eclampsia compared to normotensive pregnancy. 
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ABSTRACT (IsiZulu)  
 Isendlalelo nesingeniso: I-preeclampsia (PE), isifo sokunyuka kokugijima kwegazi esihlasela 
umuntu wesifazane ngesikhathi ekhulelwa, iyimbangela enkulu yokushona kukamama kanye 
nokugula komzimba emhlabeni wonke jikelele. I-Endothelin-1 (ET-1) iyi-vasoconstrictor 
enamandla ebamba iqhaza elibalulekile ekungasebenzi kahle kwamaseli we-endothelial, ibuye ibe 
nomthelela ekuthuthukeni kwe Preeclampsia. Lolu cwaningo beluhlola iqhaza le-ET-1 kubantu 
besifazane abanegciwane lesandulela ngculaza Kanye ne Preeclampsia ngesikhathi esisodwa. 
 
Indlela yokwenza: Inani labantu abacwaninguyo lingama-72, lihlukaniswa ngokwamaqembu 
ezinhlobo zokukhulelwa i.e., i-Abangenaso isifo (Normatensive) abangama-36 kanye nabanesifo 
se Pre-eclampsia abangama-36-, abuye aphindwa yahlukaniswa ngesimo seegciwane lesandulela 
ngculaza. Amazinga we-ET-1 asehlaziywa ngokusebenzisa iBioplex Immunoassay.  
 Imiphumela: Ukuthola amandla wobudala, iminyaka yokuthomba, umfutho wegazi ne-diastolic 
kubonakale kwenza umehluko kuwo amaqembu ocwaningo (p < 0.05). Amazinga we-ET-1 
akhuphuke kakhulu ekukhulelweni kwe-PE uma kuqhathaniswa nokukhulelwa okujwayelekile 
kungakhathalekile ukuthi sinjani isimo segciwane lesandulelaNgculaza (p ≤ 0.0418).  
Isiphetho: Lolu cwaningo lubone ukwanda okungabalulekanga kwe-ET-1 eqenjini labanepre-
eclampsia Kanye negciwane lesandulela ngculaza kuqhathaniswa nabane Preeclampsiankodwa 
bengenalo igciwane lesandulela ngculaza. I-ET-1 ibonakale yanda kakhulu ekukhuliseni i-pre-
eclampsia uma kuqhathaniswa nokukhulelwa okujwayelekile 
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INTRODUCTION AND BACKGROUND LITERATURE 
1.0 PROBLEM IDENTIFICATION 
Maternal mortality and morbidity.  
In September 2000, the eight United Nations (UN) Millennium Development Goals (MDGs) was accepted 
worldwide. The fifth MDG, a global health priority, targeted a decrease in the maternal mortality ratio 
(MMR) by 75% between 1990 and 2015 (WHO, 2014). Despite non-attainment of MDG5 in 2015 by many 
developing countries, a positive change was reported. In the sub-Saharan Africa region there was a slow 
regression in the MMR due to the effect of HIV/AIDS (Alkema et al., 2016). There was the introduction of 
the Sustainable Development Goals (SDGs) in 2015, which also targeted to reduce the global MMR to less 
than 70 deaths per 100 000 livebirths by the year 2030 (WHO, 2015). 
In South Africa, obstetric haemorrhage is the most common direct cause of maternal death accounting for 
16.9 % of maternal deaths, followed by hypertensive disorders in pregnancy (14.8 %) (Saving Mothers 
Report, 2018). Maternal deaths due to hypertension have dropped by 18% in the last 3 trienniums (Saving 
Mothers Report, 2015). Non-pregnancy related infections account for 34.7 % of all maternal deaths (Saving 
Mothers Report, 2015). Two- thirds of all maternal deaths are attributed to HIV infection (Moodley, 2018). 
 
1.1 HUMAN IMMUNODEFICIENCY VIRUS INFECTION 
The Human Immunodeficiency Virus (HIV) is a lentivirus that causes infection and immune suppression 
resulting in an increased susceptibility to opportunistic diseases (Bennett et al., 2013). The genetic material 
of the lentivirus is carried in the form of RNA which is then reverse transcribed to DNA by reverse 
transcriptase, a viral encoded enzyme. Following reverse transcription, viral DNA is integrated into the host 
cell nucleus which is further translated into viral proteins (Brik et al., 2003). HIV infection is predominantly 
caused by HIV-1 whilst HIV-2 has lower virulence and transmission and is mostly localized in West Africa 
(Bull et al., 2015).  
 
HIV attacks T cells that exhibit the CD4 antigen on their surface. HIV infection requires cellular and viral 
membranes fusion, a process mediated by viral envelope glycoproteins (gp41 and gp120) and receptors 
(CD4 and co-receptors CCR5 or CXCR4) on the target cell (Brik et al., 2003; Maartens et al., 2014). The 
virus infects cells bearing CD4 and chemokine receptors including monocytes and macrophages, dendritic 
cells and resting CD T cells. 
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HIV is transmitted across the mucosal membranes through receptors CCR5 or CXCR4 for entry and is 
resistant to interaction with dendritic cells as well as interferon-α (Maartens et al., 2014). HIV infection 
causes a gradual decrease in CD4 lymphocytes which lowers immunity (Vidya Vijayan et al., 2017), 
leading to a variety of opportunistic diseases or eventually the risk of AIDS (Bull et al., 2015). 
 
Central nervous system complications associated with HIV-1 infection manifests as neuronal dysfunction 
associated with monocyte infiltration into the brain, myelin pallor and the formation of multinucleated giant 
cells (Didier et al., 2002). These morbid attributes result in the synthesis and accumulation of nitric oxide 
(NO), arachidonic acid metabolites, and soluble factors such as endothelin-1 (ET-1) (Didier et al., 2002). 
HIV infection is also linked with a chronic inflammatory process (Feijoo et al., 2014). 
  
The routine use of highly active antiretroviral therapy (HAART) has resulted in a drastic and sustained 
decrease in mortality and morbidity from HIV infection and the risk of mother-to-child transmission (Suy 
et al., 2006). HIV can be transmitted through sexual, perinatal (mother-to-child) or blood transmission 
(exposure to contaminated blood) (Karim et al., 2007). Over 80% of new infections in women are sexually 
transmitted with the majority of affected women living in sub-Saharan Africa (UNAIDS, 2015).  
 
1.1.1 Prevalence of HIV  
.South Africa (SA) has the highest HIV/AIDS prevalence in the world (13.5%) with 7.97 million of the 
population in 2019 being HIV positive (Stats SA, 2019). Provincial variation of HIV-prevalence exists with 
KwaZulu-Natal (KZN) been the highest and is considered the epicenter of the global HIV/AIDS pandemic 
with a prevalence of 18.1% (Simbayi et al., 2019). Over a fifth of South African women in their 
reproductive ages (15–49 years) are HIV positive (Stats SA, 2019). Approximately 4.2 million South 
African women of ages (15+) are infected with HIV (UNAIDS, 2018).  
In 2018, UNAIDS reported that 4.4 million people were receiving antiretroviral therapy (ART) in SA. Due 
to the success of the ART rollout, the South African National Department of Health drafted a new policy 
regarding an improved ART rollout in 2016 (Mukumbang et al., 2019). Provision of ART to women before 
and during pregnancy and breastfeeding prevents mother-to-child transmission (MTCT) and improves 
health and survival of mothers (WHO, 2016a), which itself benefits the health of their children (Newell et 
al., 2004). Seventy six percent of pregnant women living with HIV (over 1 million women) receive ART 
annually to prevent MTCT of HIV (Bailey et al., 2018). 
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1.2 PREECLAMPSIA  
Preeclampsia (PE) is a multi-system disorder of vascular dysfunction that manifests as hypertension 
(>140/90 mm Hg) with/without proteinuria (>300mg/ 24-hour urine) during pregnancy (Brown et al., 
2018). PE is also associated with coagulation abnormalities and decreased uteroplacental flow (Walsh, 
2007) and can result in fetal growth restriction (FGR), stillbirth, abruptio placentae, and preterm labor with 
intact membranes (Nakimuli et al., 2014). Maternal organ dysfunction associated with PE manifests as 
eclampsia, HELLP syndrome (elevated liver enzymes, haemolysis) and thrombocytopenia (low platelet 
count) (WHO, 2016b; Rana et al., 2019). Pulmonary oedema and myocardial ischaemia or infarction are 
part of the cardiorespiratory complications resulting from PE (Mol et al., 2016; Rana et al., 2019). Women 
with severe PE might experience symptoms of visual disturbances (including blindness), headaches, 
epigastric pain, or nausea and vomiting (Mol et al., 2016). 
 
1.2.1 Epidemiology of Preeclampsia 
PE is a global concern, complicating approximately 10% of all pregnancies and is a major cause of maternal 
and perinatal morbidity and mortality (Mattar et al., 2004; George and Granger, 2011; Kalumba et al., 2013; 
Craici et al., 2014; English et al., 2015; Herse and LaMarca, 2013). According to the World Health 
Organization (WHO), nearly one-tenth of all maternal deaths are associated with hypertensive disorders of 
pregnancy in Asia and Africa, whereas in Latin America one-quarter of all maternal deaths are related to 
hypertensive complications. In South Africa (SA), maternal deaths due to hypertension in pregnancy is 
approximately 14%, of which 83% is due to PE development (Saving Mothers Report, 2017). In KZN, the 
incidence of PE is 12% (Gathiram and Moodley, 2016).  
 
1.2.2 Classification of Preeclampsia 
Based on gestational age, PE may be clinically divided into two sub-types: early-onset preeclampsia 
(EOPE) <34 gestational weeks, and late-onset preeclampsia (LOPE) >34 gestational weeks (Raymond et 
al., 2011; Lisonkova et al., 2014).  
EOPE is considered a fetal disorder associated with a plethora of outcomes including placental dysfunction, 
low birth weight, perinatal death, multiorgan dysfunction, reduction in placental volume, abnormal uterine 
and umbilical artery Doppler evaluation and intrauterine growth restriction (Aksornphusitaphong et al., 
2013).  
LOPE is regarded as a maternal disorder with minimal changes to placental pathophysiology, however 
induced maternal inflammatory response leads to PE development, eclampsia and maternal death 
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(Lisonkova et al., 2014). LOPE presents more favourable maternal and neonatal outcomes to EOPE 
(Raymond et al., 2011). 
Severe PE may be described as the maternal systolic blood pressure ≥160 mmHg or diastolic blood pressure 
≥110 mmHg confirmed in 15 minutes; eclampsia, proteinuria ≥5 g/24hours, HELLP syndrome, acute 
pulmonary oedema, neurological disorders, polykinetic tendon reflexes, oliguria <500 cc/day, creatinine 
>120 µmol/L, intrauterine growth retardation and fetal death in utero (Brown et al., 2018), however, there 
are different views on the definition of severe PE (ACOG, 2019). 
 
1.2.3 Preeclampsia aetiology 
The exact aetiology underlying PE remains elusive however, it is believed to originate from placental 
deficiency (George and Granger, 2011), emanating from an abnormal cytotrophoblast invasion with 
resultant non-physiological transformation of the maternal spiral arteries within the myometrium (Naicker 
et al., 2013; Hod et al., 2015).  
Normal placental development begins with cytotrophoblast invasion of the maternal spiral arteries. These 
invasive cytotrophoblasts originate in the fetus. Following vascular invasion, in a process called “vascular 
mimicry” or “pseudovasculogenesis” the cytotrophoblasts differentiate into an endothelial phenotype. In 
pre-eclampsia, invasion of the spiral arteries is shallow due to failure of cytotrophoblasts differentiation 
from an epithelial to endothelial phenotype (Wang et al., 2009).  The resultant invasion transforms the spiral 
arteries from small-caliber resistance vessels to high-caliber capacitance vessels to give apposite support 
for the growing fetus (Figure 1.1) (Lam et al., 2005). 
PE is characterised by increased oxidative stress and decreased antioxidants. Levels of glutathione, iron 
binding capacity, superoxide dismutase and vitamin A, C, E are altered in the maternal circulation 
(Rumbold et al., 2008). Due to the decrease in superoxide dismutase activity and vitamin E, the iron 
concentration and superoxide anion concentration increases resulting in significant oxidative stress 
(Siddiqui et al., 2010). PE pathophysiology includes an imbalance between thromboxane (a potent 
vasoconstrictor) and prostacyclin (a potent vasodilator); thromboxane is favored by the imbalance, 
oxidative stress, activation of circulating leukocytes and vascular cell dysfunction (Walsh, 2007).  
Endothelial dysfunction is caused by increased oxidative stress and enhanced maternal inflammatory 
response (Margaritis, 2019). 
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Figure 1.1: Abnormal placentation in preeclampsia. In normal placentation (a), invasion of maternal spiral arteries by 
invasive cytotrophoblasts transforms their capacitance from small to high caliber resistance vessels to pertinently 
support the growing fetus. Cytotrophoblasts differentiate from an epithelial to endothelial phenotype. In preeclampsia 
(b), cytotrophoblasts fail to differentiate into an invasive endothelial phenotype instead have a shallow invasion of 
spiral arteries and remain small caliber resistance vessels [adapted from (Wang et al., 2009)]. 
 
1.2.4 Renin-Angiotensin Aldosterone System 
The renin-angiotensin aldosterone system (RAAS) regulates extracellular fluid volume, electrolyte balance 
and arterial pressure to maintain vascular tonicity (Irani and Xia, 2008, Patel et al., 2017). Agitation of the 
RAAS can interrupt normal blood pressure, resulting in chronic or acute diseases, or even sudden death 
(Patel et al., 2017). Renin cleaves angiotensinogen to 10- amino acid peptide called angiotensin-l (Ang-1) 
in a rate-limiting step of the RAAS cascade (Irani and Xia, 2008). Ang-1 is converted to angiotensin-ll 
NORMAL 
PRE-ECLAMPSIA 
A 
B 
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(Ang-ll) in a reaction catalysed by the angiotensin converting enzyme in the RAAS (Aung et al., 2017). 
Ang-ll constricts smooth muscles as it exhibit its vasoactive role in increasing the blood pressure (Patel et 
al., 2017). High renin levels causes endothelial impairment and results in high Ang-ll activity (Patel et al., 
2017). PE is marked by the increase in systemic vascular resistance with hypovolemia and a low cardiac 
output which is followed by the suppression of the RAAS (Saleh et al., 2016b). 
Alternatively, suppression of the RAAS results in increased production of auto-antibodies to the Ang-ll 
type 1 receptor from the placenta of preeclamptic patients (Saleh et al., 2016b). PE is also affected by a 
dysfunctional RAAS with an expanded Ang-ll sensitivity before disease onset characterized by endothelial 
dysfunction (Saleh et al., 2016b). Ang-ll type 2 receptor is implicated in the increased vasoconstrictor 
response to Ang-ll in PE (Saleh et al., 2016b).  
It has been hypothesized that the activity of Ang-II affects ET-1 synthesis, similar to the effect of ET-1 on 
the RAAS (Rossi et al., 1999). The final pathway leading to hypertension, renal toxicity and RAAS 
suppression in PE appears to be the endothelin system (Saleh et al., 2016b). 
 
1.2.5 Risk factors for Preeclampsia development 
The risk of PE is markedly increased in women who are genetically predisposed to the disease by mothers 
who were previously affected by PE (Mogren et al., 1999; Mol et al., 2016). PE also substantially increases 
the risk of post-partum depression and decreases health-related quality later on in life (Mol et al., 2016). 
Obesity is a risk factor of PE although the involved mechanisms are still unknown. An increase in pregnancy 
body mass index (BMI) leads to an increased risk of PE development (Walsh, 2007). Moreover, the risk of 
PE development is greater for women who have partners that previously fathered a preeclamptic pregnancy 
(Hawfield and Freedman, 2009).  
 
Chronic kidney disease, hypertension in pregnancy, previous PE, diabetes (type 1 and type 2), and 
autoimmune disorders, including antiphospholipid syndrome and lupus erythematosus are strong risk 
factors of PE (Creasy and Resnik, 2004; Duckitt and Harrington, 2005). Moderate risk factors of PE include 
(i). first pregnancy, (ii). a pregnancy interval greater than 10 years, (iii) age of 40 years or more, (iv). body 
mass index of 35 kg/m2 or more, (v). polycystic ovarian syndrome and (vi). multiple pregnancy (Mol et al., 
2016). Kidney donors are more likely to develop PE than matched women who had not donated a kidney 
(Deshpande et al., 2011).  
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1.2.6 Prevention of Preeclampsia 
Termination of pregnancy/ delivery of the fetus and placenta is the only ultimate treatment for PE, although 
some women with PE also exhibit a transitory aggravation of the disease in the postpartum period (Hawfield 
and Freedman, 2009; WHO, 2016b). As a result, preventive measures for PE development has become a 
key research focus and has shown promise in recent years. Based on the findings of individual patient data 
(IPD), aspirin was found to be a more suitable drug to prevent PE (Mol et al., 2016). PE is associated with 
low serum calcium concentration and low dietary calcium. As, a result, women with low dietary calcium 
require high dose calcium supplementation especially in the second half of pregnancy to reduce PE (WHO, 
2016b). L-arginine, a nitric oxide precursor, reduces the risk of PE when given in combination with 
antioxidants (Noris et al., 2005).  
 
1.2.7 Preeclampsia complicated by HIV infection 
It is plausible to assume that preeclamptic pregnancies complicated by HIV infection are a representation 
of opposing immune responses (Haffejee et al., 2013). Kalumba et al. (2013) stated that the rate of PE 
development is lower in HIV-positive pregnant women that the general population. HIV infected women 
have a higher risk of PE compared to women without HIV and the risk is increased in women receiving 
highly active antiretroviral therapy HAART therapy (Sansone et al., 2016). HIV infection could possibly 
inhibit or block factors that may play a vital role in PE development (Mattar et al., 2004).  
PE was an uncommon complication of pregnancy in HIV-infected women prior to the administration of 
HAART (Suy et al., 2006).  Nonetheless, HAART restores immunity in the infected individual and results 
in an improved response which contributes to increased susceptibility to PE development (Kalumba et al., 
2013; Maharaj et al., 2017). 
 
1.3 ENDOTHELIN-1  
Endothelin-1 (ET-1) is a 21-amino acid peptide isolated from endothelial cells and is regarded as the most 
potent vasoconstrictor peptide in the cytokine family (Didier et al., 2002; Freeman et al., 2014). It forms 
part of the three known endothelin isoforms, specifically encoded by a distinct peptide, but results from an 
identical two-step metabolic pathway (Freeman et al., 2014).  ET-1 is the most abundant isoform in vivo, 
derived from a longer 203-amino acid precursor known as preproendothelin-1, which is converted into the 
intermediate precursor big ET-1 (Figure 1.2). The endothelin converting enzyme (ECE) generates ET-1 by 
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cleaving the bond between Trp21 and Val 22 of big ET-1 (George and Granger, 2011; Freeman et al., 2014; 
Davenport et al., 2016; Yanagisawa et al., 1988; D'Orleans-Juste et al., 2003). ECE is a zinc-dependent 
metallo-endopeptidase found in several cell types such as smooth muscle cells, endothelial cells, 
macrophages and cardiomyocytes (Takahashi et al., 1995; Barnes and Turner, 1997; Pelayo et al., 2011).  
ET-1 has two endothelin receptors viz., ET-1 type A (ETA) and ET-1 type B (ETB). ETA receptor found on 
vascular smooth muscle and are essential regulators of ET-1 dependant vasoconstriction and cellular 
proliferation, and ETB is located on renal epithelial and vascular endothelial cells (George and Granger, 
2011). ETA receptor activation by ET-1 mediates vasoconstriction through stimulation of phospholipase C 
with resultant formation of inositol triphosphate (IP3) that induces the release of Ca2+ from endoplasmic 
reticulum stores. Binding of ET-1 to ETA promotes calcium influx, proliferation and contraction of smooth 
muscle cells (Freeman et al., 2014). In contrast, the binding of ET-1 to ETB  receptor mediates vasodilation 
through activation of the Phosphatidylinositol 3-kinase/Protein B kinase (PI3/Akt) pathway, followed by 
activation of the endothelial nitric oxide (NO) synthase generating NO (Figure 1.3) (Khimji and Rockey, 
2010). 
Hypoxia induces the synthesis of ET-1 in the endothelium (Freeman et al., 2014). The vasoconstrictive 
properties of ET-1 stimulates DNA synthesis and proliferation in pulmonary arterial smooth muscle cells 
(Sandoval-Gutierrez et al., 2015). Additionally, ET-1 has neuroregulatory and physiologic functions. ET-1 
is further implicated as a mediator of cerebrovascular responses linked with subarachnoid haemorrhage and 
ischemic strokes (Didier et al., 2002). 
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Figure 1.2: Endothelin-1 development from prepro-endothelin (adapted from (Kawanabe et al., 2011)).  
 
1.3.1 The role of endothelin-1 in Preeclampsia 
The mRNA of ET-1 has been found in the human placenta (Fiore et al., 2005). ET-1 dysregulation occurs 
in PE, specifically through the increase of circulating ET-1 levels (George and Granger, 2011; Zhou et al., 
2011). The altered ET-1 system in PE causes an increased ECE activity in the maternal circulation with 
elevated tissue production of preproET-1 mRNA in comparison to normal ET-1 functioning in healthy 
pregnant or non-pregnant women (George and Granger, 2011).  
Endothelial dysfunction induced by soluble fms-like tyrosine kinase-1 and soluble endoglin results in ET-
1 overproduction thereby leading to hypertension and proteinuria (Aggarwal et al., 2012). ET-1 causes 
oxidative stress in placental and human endothelial cells and has cytotoxic effects on trophoblast cells, 
thereby suggesting that ET-1 is the key link between the primary placental cause and the secondary systemic 
maternal disorder of PE (Fiore et al., 2005; Aggarwal et al., 2012).  
The vitality and proliferation rate of trophoblast cells is decreased by ET-1 (Fiore et al., 2005). Moreover, 
proliferation, function and migration of trophoblasts are deficient in PE (McNally et al., 2017). However 
during PE, placental ischemia resulting from reduced uterine perfusion pressure enhances formation of ET-
1, which plays a role in mediating hypertension as a rescue mechanism to enhance maternal blood flow 
through the placenta by increasing maternal blood pressure (Fiore et al., 2005). 
ENDOTHELIN-1 SYNTHESIS 
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Figure 1.3: Schematic figure representing conditions of a healthy artery and endothelial dysfunction. In healthy 
arteries, ET-1 production is reduce, and NO is preserved resulting in vasorelaxation. In endothelial dysfunction 
however, an overproduction of ET-1 exists, resulting in an over-expression in smooth muscles and macrophages. ETB 
is expressed in the smooth muscles and mediates vasoconstriction [adapted from (Böhm and Pernow, 2007)].  
 
 
1.3.2 Endothelin-1 in HIV infection 
HIV viral antigens found on pulmonary endothelium have been reported to stimulate abnormal growth, 
apoptosis and proliferation (Mette et al., 1992). In HIV infection, ET-1 production from endothelial cells 
and inflammatory cells are affected by HIV-related proteins (Humbert, 2008). Glycoprotein 120 (gp120) is 
a viral protein that targets human lung endothelial cells, assists in the binding and entry of HIV into 
macrophages, stimulates the secretion of ET-1, and increases apoptosis (Sandoval-Gutierrez et al., 2015).  
Additionally, the HIV viral protein Tat, boosts ET-1 production in astrocytes indicating enhanced ET-1 
synthesis during infection (Freeman et al., 2014). ET-1 enhances neuropathology of HIV through the 
facilitation of monocyte transmigration into the brain (Didier et al., 2002, Freeman et al., 2014). 
 
 
1.4 AIM OF STUDY 
In light of the problem identification statement, the aim of this study is to investigate the role of the 
vasoconstrictor, endothelin-1 in the pathogenesis of HIV associated pre-eclampsia. 
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1.4.1 Objectives 
 To determine the effect of pregnancy type (normotensive vs preeclamptic) on the concentration of 
endothelin-1, irrespective of HIV status (HIV positive and HIV negative) utilizing BioPlex 
Multiplex Immunoassay. 
 To establish the effect of HIV status (HIV positive vs HIV negative) on the concentration of 
endothelin-1, irrespective of pregnancy type (normotensive vs preeclamptic). 
 To compare and contrast the concentration of endothelin-1 across all study population based on 
pregnancy type (normotensive vs preeclamptic) and HIV status (HIV positive vs HIV negative). 
 To correlate maternal clinical findings with endothelin-1 across study population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER TWO 
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MANUSCRIPT 
 
Original Article: Is endothelin-1 concentration altered in HIV-associated preeclampsia? 
 
Chapter 2 is presented as an original article which has been submitted to a DoHET accredited 
international journal. 
The first author is the author of this thesis (MH Mthembu) contributing to the literature and protocol 
review, experimental procedures and interpretation of the results. 
This article investigates the concentrations of Endothelin-1 in serum samples of South African women 
with African ancestry. This study investigates concentration of this vasoconstrictor in the duality of HIV 
and Preeclampsia. 
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ABSTRACT 
Objective: South Africa has the fourth-highest HIV/AIDS prevalence rate in the world. Maternal mortality 
emanating from HIV infection and preeclampsia is unacceptably high. Endothelin-1 (ET-1) is a powerful 
vasoconstrictor that plays a crucial role in endothelial cell dysfunction, a characteristic feature of 
preeclampsia development. In light of the paucity of data on ET-1 in HIV infection comorbid with 
preeclampsia, this study assessed the role of ET-1 in HIV infected preeclamptic women.  
Method: The study population (n = 72) was grouped according to pregnancy type i.e., normotensive (n = 
36) and preeclamptic (n = 36) and was further stratified by HIV status. ET-1 levels were quantified using 
the Bioplex immunoassay.  
Results: Gravidity, gestational age, systolic and diastolic blood pressure were significant across the study 
groups (p < 0.05). The concentration of ET-1 was significantly elevated in preeclamptic vs normotensive 
pregnancies, regardless of HIV status (p = 0.0418). The expression of ET-1 was similar between HIV 
positive versus HIV negative groups, irrespective of pregnancy type (p = 0.8512). There was no significant 
difference detected across all study groups (p = 0.2349). 
Conclusion: HIV status did not influence ET-1 in HIV associated preeclampsia. In light of the fact that 
the HIV accessory protein, Tat is a potent angiogenic factor hence would neutralize the antiangiogenic 
effect of ET-1. Notably, HAART may have also influenced ET-1 levels in HIV infected women. 
 
Keywords: Endothelin-1, Hypertension, HIV infection, Preeclampsia 
 
Running title: Endothelin-1 in HIV associated preeclampsia 
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INTRODUCTION 
Hypertensive disorders of pregnancy remain a global threat to maternal mortality. Developing countries are 
faced with the greatest burden of hypertension in pregnancy (1), with preeclampsia (PE) among the leading 
causes of maternal deaths (2). In South Africa, PE accounts for approximately 83% of all maternal deaths 
(3).  
Furthermore in South Africa, 20.4% of non-pregnancy related deaths are attributed to HIV infection (4). In 
the province of KwaZulu-Natal (KZN), the prevalence of HIV infection in pregnancy is approximately 
41.1% (5). It is controversial whether the co-existence of HIV infection and PE leads to a neutralization, 
increase or decrease of the immune response (6-8). Some studies suggest HIV-positive women receiving 
highly active antiretroviral therapy (HAART) are at an increased risk of developing PE than untreated 
women due to the immune reconstitution effects of HAART (8, 9) 
In PE, the failure to remodel vascular uteroplacental arteries due to inadequate trophoblast invasion and 
non-conversion of maternal spiral arteries leads to placental ischaemia and a state of under perfusion (10). 
In response, the placenta secretes soluble factors into the maternal circulation resulting in an exacerbated 
maternal inflammatory response due to an increase of anti-angiogenic factors (11). Generally, a balance 
between pro- and anti-angiogenic factors are necessary for placental development in normal pregnancy, 
however in PE, a paradigm shift in angiogenesis as a result of dysfunctional syncytiotrophoblast leads to 
maternal vascular endothelial dysfunction and resultant clinical symptoms of the disease (12). 
These endothelial abnormalities leads to the enhanced reproduction of vasoconstrictors viz., endothelin and 
superoxide, an increased sensitivity to the hormone angiotensin II and decreased formation of the 
vasodilator, nitric oxide (13).  
Endothelins belong to a family of three 21-amino acid peptides, of which endothelin-1 (ET-1) is the most 
prominent and potent vasoconstrictor, produced by endothelial cells and placental syncytiotrophoblasts. 
ET-1 activity is mediated by the endothelin receptors, ETA and ETB. ET-1 exerts its vasoconstriction via the 
ETA receptor, contributing to high blood pressure in PE (14). ET-1 is elevated in PE (15).  
The secretion of other soluble factors in the maternal circulation including soluble FMS-like tyrosine 
kinase-1 (sFlt-1), inflammatory cytokines and angiotensin II type-1 receptor auto-antibodies have been 
shown to induce hypertension in PE through the production of ET-1 (16, 17). The production of these 
causative agents of endothelial cell injury reduces the synthesis of vasorelaxing agents with a resultant 
increase in vasoconstriction (14). This provides a potential mechanism through which ET-1 activity 
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promotes blood pressure elevation in PE. Notably in PE, there is an increased vascular resistance with 
hypovolemia and a low cardiac output preceded by the suppression of RAAS (18). 
HIV infection is associated with a chronic inflammatory process, similar to PE. The release of ET-1 and 
other inflammatory markers may directly contribute to endothelial damage. The HIV accessory protein Tat 
mimics VEGF and is a potent angiogenic factor.    
In light of the synergistic effect of ET-1 in HIV infection and PE, the aim of this study is to investigate the 
role of ET-1 in HIV-associated preeclampsia within the KZN province.  
 
METHODS AND MATERIALS 
Study Population 
This is a prospective experimental study utilizing retrospectively collected samples from a large regional 
hospital in eThekwini, KZN. Institutional, regulatory approval and patient informed consent was obtained 
(BCA 338/17). The study population consisted of 72 subjects, preeclamptic (n=36) and normotensive 
(n=36) pregnant women, further stratified by HIV status into HIV-negative (n=18) and HIV-positive (n=18) 
subgroups. Preeclampsia was defined as sustained systolic blood pressure ≥ 140 mmHg and diastolic blood 
pressure 90 mmHg or greater, taken at least 4 hours apart, after 20 weeks’ gestation in a previously 
normotensive patient (19). Proteinuria was defined as urine protein concentration of ≥300 mg/dl or 1+ on 
a urine dipstick in at least two random specimens collected at least 4 hours apart. HIV status was determined 
by a rapid test and CD4 count was carried out for all HIV-positive women. Exclusion criteria for the PE 
group was chorioamnionitis, chronic hypertension, eclampsia, and abruptio placentae; intrauterine death, 
pregestational diabetes, gestational diabetes, and chronic renal disease; systemic lupus erythematosus, 
sickle cell disease, and antiphospholipid antibody syndrome; and thyroid disease, cardiac disease, and 
active asthma requiring medication during pregnancy and pre-existing seizure disorders. 
 
Bio-Plex Multiplex Immunoassay 
Serum samples were stored at -80℃ until use. The concentration of ET-1 was quantified using the Human 
Angiogenesis/Growth Factor Magnetic Bead Panel 1 (catalogue number HAGP1MAG-12K, EMD 
Millipore Corporation, USA) following the manufacturer’s instructions. Serum samples were diluted in 1:3 
using Assay Buffer. Assay buffer (200µl) was added to a 96 well plate, followed by the addition of the 
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standards, control, assay buffer, matrix solution, samples and antibody-coupled magnetic beads to the 
appropriate wells. The plate was incubated overnight at 2-8℃. Thereafter the plate was washed three times 
with 10X wash buffer. Biotinylated detection antibodies were added to each well and incubated for 1 hour 
at room temperature. The reaction was completed by the addition of streptavidin-phycoerythrin (SA-PE) 
and incubated for 30 minutes at room temperature. Post final washing (X3) drive fluid was added and the 
plate was read using the Bio-Plex® MAGPIX™ Multiplex Reader (Bio-Rad Laboratories Inc., USA) and 
data was analyzed using the MILLIPLEX® Analyst 5.1 software.  
 
Statistical analysis 
Data was analysed using GraphPad Prism 5.00 for Windows (GraphPad Software, San Diego, California 
USA). The Kolmogorov Smirnov normality test indicated non-parametrically distributed data. A Mann-
Whitney U test was to determine significance based on pregnancy type (normotensive vs. preeclamptic) 
and HIV status (negative vs. positive). One-way ANOVA analysis of variance test along with Dunn’s post 
hoc test (for multiple comparisons) was used to determine statistical significance across all study groups. 
The non-parametric data was presented as median and interquartile range. A value of p < 0.05 was 
considered statistically significant.  
 
RESULTS 
 Clinical findings and patient demographics 
Table 1 outlines the patient clinical and demographic data across the study group. A significant difference 
was detected for gestational age, systolic and diastolic BP (p < 0.0001) as well as gravidity (p=0.0125). 
Maternal age, systolic BP, diastolic BP and maternal weight were higher in preeclamptic vs normotensive 
pregnancies. There was no significant difference for maternal age (p=0.7859) and parity (p=0.5188) across 
all groups. Similarly, maternal weight showed no significant difference across all groups (p=0.1478).  
Table 1: Clinical demographics and patient data across all study groups (n=72) 
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 Preeclamptic 
HIV-positive 
(PE+) (n=18) 
Preeclamptic 
HIV-negative 
(PE-) (n=18) 
Normotensive 
HIV-positive 
(N+) (n=18) 
Normotensive 
HIV-negative 
(N-) (n=18) 
p value 
Maternal age (years) 27.50 (34.50-
24.00) 
25.50 (38.50-
19.00) 
29.00 (30.25-
25.75) 
25.00 (32.00-
20.00) 
0.8046 
Parity  2 (4-0) 1 (4-0) 1 (3-0) 1 (4-0) 0.5188 
Gravidity  3 (5-1) 1 (2-1) 2 (4-0) 2 (4-1) 0.0125* 
Gestational age (weeks) 32 (39-24) 35 (40-25) 39 (42-26) 40 (41-37) <0.0001*** 
Systolic blood pressure 
(mmHg) 
167.50 (190-149) 168 (206-146) 120.50 (134-99) 119 (132-92) <0.0001*** 
Diastolic blood pressure 
(MmHg) 
103.50 (146-89) 105.50 (130-72) 76.50 (90-32) 70 (82-52) <0.0001*** 
Maternal weight (kg) 69.50 (106.80-54) 75.50 (120-
50.60) 
68 (81-55.20) 75 (94-58) 0.1478 
   Data represented as median and interquartile range. * p value < 0.05 was considered statistically significant. #Parity and Gravidity       
represented as median and range. 
 
Concentration of serum ET-1 
Pregnancy type 
Regardless of HIV status, there was a significant increase of serum ET-1 in PE (median = 14.02 pg/mL, 
IQR = 23.47 – 0.19 pg/mL) compared to normotensive (median = 3.94 pg/mL; 95% CI: 11.66 – 4.68) group 
(Mann-Whitney U=468.50; p=0.0418) (Figure 1a). 
HIV status 
There was no significance difference in the expression of ET-1 between HIV positive (median = 11.31 
pg/mL, IQR = 18.14 – 0.13 pg/mL) versus HIV negative (median = 6.04 pg/mL; 95% CI: 15.76 – 6.94 
pg/mL) groups irrespective of pregnancy type (Mann-Whitney U=631.00; p = 0.8512) (Figure 1b). 
Across all groups 
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There was no significant difference detected across all study groups (p = 0.2349) as illustrated in Table 2 
and Figure 1c.  
Table 2: Concentration of ET-1 (pg/ml) observed across all groups 
 Preeclamptic pregnancies Normotensive pregnancies  
 Preeclamptic HIV 
positive (n=18) 
Preeclamptic 
HIV negative 
(n=18) 
Normotensive HIV 
positive (n=18) 
Normotensive HIV 
negative (n=18) 
p- value 
ET-1 
(pg/ml) 
15.24 (0.13 -25.33)  12.67 (2.99-
23.94) 
6.04 (0.13-14.63) 3.94 (0.38-11.99) p = 0.2349 
Value are represented as median and interquartile range 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
 
 
 
 
 
 
 
 
 
 
 
ET-1: endothelin-1; N-: normotensive negative; N+: normotensive positive; PE-: preeclamptic negative; PE+: preeclamptic positive 
Figure 1: Endothelin-1 concentrations, (a) normotensive vs preeclamptic, * ET-1 concentrations are significantly 
increased in preeclamptic vs normotensive (p = 0.0418); (b) HIV positive vs HIV negative, no significant difference 
was noted (p = 0.8512); (c) across all groups, no significant difference was observed (p = 0.2349).  
 
DISCUSSION 
This study demonstrates an upregulation of serum ET-1 concentration in PE compared to normotensive 
pregnant women, regardless of their HIV status. This finding is corroborated by various other studies (20-
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24). Our findings were predicted as ET-1 is a potent vasoconstrictor which plays a role in the regulation of 
the vascular tone in PE (25). The peptide advances ventricular and vascular remodeling, acute and chronic 
increases in vascular resistance and inflammation in models of heart failure (26). Existence of endothelial 
damage linked with increased ET-1 is crucial in PE development. ET-1 upregulation in the 
hyperinflammatory state of PE may be due to leakage to the systemic circulation caused by endothelial 
damage, increase in placental production and feedback mechanism between NO and ET-1 (27, 28). 
Pathophysiological conditions such as hypoxia as well as hormones such as thrombin, adrenaline, 
vasopressin, angiotensin II (Ang II), insulin and cytokines upregulate ET-1 production (26, 29). (30) 
demonstrated increased expression of hypoxia-inducible factor-1 (HIF-1α) in PE implicating placental 
hypoxia and endoplasmic reticulum stress in the development of PE.  
Shear stress regulates the production and release of ET-1 from endothelial cells. The shear stress receptor 
of endothelial cells triggers an increase in the rate of blood flow eliciting vasodilation (31). However, failure 
of shear stress-mediated dilation in myometrial arteries may contribute to the defective trophoblast cell 
invasion and consequential decreased blood flow to the neonate, as observed in PE (32). As a result of shear 
stress receptor activation, NO is produced and released from the endothelium (33).   
Endothelial dysfunction also affects the action of ET-1 through the bioavailability of nitric oxide (NO) 
which opposes the vasoconstrictive nature of ET-1 (33). A study by (34) supports the hypothesis that a 
decrease in NO production inhibits endothelium-dependent vasorelaxation which disturbs vascular 
homeostasis and elicits endothelial dysfunction. 
In our study, based on HIV status, ET-1 was slightly increased albeit non-significantly in HIV positive 
compared to HIV negative participants, regardless of pregnancy type.  Similar to our findings, Feijoo et al. 
(2014) reported higher plasma levels of ET-1 in HIV infected patients compared to non-infected patients. 
The mechanism attributed to the increase in ET-1 in the HIV infected population is not clearly elucidated. 
Presumably, ET-1 release is a product of endothelial damage caused by chronic inflammation emanating 
from the viral infection (35). 
Notably, HIV-related proteins such as gp120 stimulate the production of ET-1 from endothelial cells whilst 
the accessory protein Tat boosts ET-1 production in astrocytes (36). The HIV envelope protein gp120 is 
suggested to cause pulmonary vascular damage (37).  
The increase in ET-concentrations in our HIV-infected cohort may also be attributed to the usage of 
antiretroviral drugs viz., AZT, indinavir and highly active antiretroviral therapy (HAART) (38, 39). These 
nucleos(t)ide reverse transcriptase inhibitors (NRTIs) inhibit the action of DNA polymerase γ, responsible 
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for mitochondrial DNA replication (40). The decreased mitochondrial respiration leads to increased 
production of reactive oxygen species (ROS), which in turn stimulates the release of circulatory ET-1 (38). 
Moreover, HAART induces a dramatic increase in the release of ET-1 from human umbilical vein 
endothelial cells (38). 
(41) stated that HIV associated PE represent opposing immune responses. (42) supports this statement 
suggesting that HIV immune-depressive effects there is a link between HIV and PE.  Additionally, HIV 
infection could inhibit factors that impacts the development of PE (43). The risk of developing PE is 
increased in HIV positive women compared to uninfected women and even higher in women receiving 
HAART therapy (7). In the pre-HAART period, PE was an uncommon complication of pregnancy in HIV-
infected women compared to the general population (44). HAART induces immunocompetence in HIV 
infected pregnant women predisposing them to PE development compared to a failing immune system 
where PE will fail to thrive on (8). Similar findings were observed in a study conducted in SA by Maharaj 
et al., (2017) who reported that HAART rebuilds the immune response thereby exacerbating the already 
enhanced inflammatory response in PE.  
 
CONCLUSION 
This study demonstrates a significant upregulation of serum ET-1 levels in PE compared to normotensive 
pregnancy, validating its potent vasoconstrictor effect. We also report an elevated trend in ET-1 expression 
in HIV positive compared to HIV negative pregnant women. This finding is novel and mirrors the effect of 
HIV envelope gp 120 and accessory proteins, Tat on ET-1 production in the inflammatory ambiance of PE.  
Notable ET-1 levels remained unchanged despite the synergy of PE and HIV infection in our study 
population emanating from HAART induced oxidative stress.  However, more studies on the immune 
rejuvenation induced by HAART should be done to further understand the impact it has on the duad HIV 
associated PE. Assessing ET-1 activity in PE and HIV infection may lead to potential therapeutic strategies 
manage hypertension in pregnancy.  
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SYNTHESIS 
Maternal Mortality as described by World Health Organization (WHO) is the death of a pregnant women 
or within 42 days following termination of pregnancy, irrespective of the site and duration of pregnancy, 
from any cause aggravated by pregnancy, but not from accidental causes (Alkema et al., 2016). According 
to WHO, an estimated 800+ women die per day due to pregnancy or obstetric complications with most 
deaths recorded in sub-Saharan Africa and Asia (Kassebaum et al., 2014). HIV infection in the sub-Saharan 
Africa region is responsible for 6.4% of all maternal deaths when compared to other regions across the 
globe (Say et al., 2014). 
At the Millennium Summit in 2000, world leaders pledged to reduce maternal mortality ratio (MMR) by 
75% from 1990 to 2015 as part of the Millennium Development Goals (MDGs) (Say et al., 2014), however 
the progress of the MDG5 was slower than required (Alkema et al., 2016). There was the introduction of 
the Sustainable Development Goals (SDGs) in 2015, which also targeted to reduce the global MMR to less 
than 70 deaths per 100 000 livebirths by the year 2030 (WHO, 2015).  
Preeclampsia (PE), an obstetric disorder that complicates 3-8% of global pregnancies and a major cause of 
maternal mortality and morbidity worldwide (Carty et al., 2010). Approximately 16% of all maternal deaths 
in developed countries and 9% in Africa is attributed to PE (Khan et al., 2006, Alkema et al., 2016). The 
prevalence of PE in KwaZulu-Natal is 12% (Gathiram and Moodley, 2016) and HIV infection in pregnant 
women is estimated at 41.1% (Woldesenbet et al., 2017).  
Endothelin-1 (ET-1) is a peptide from the cytokine family and a potent vasoconstrictor. It is secreted by 
endothelial cells (Yanagisawa et al., 1988) and placental syncytiotrophoblasts (Saleh et al., 2016b). ET-1 
acts through two receptors; ETA and ETB, these receptors are responsible for vasoconstriction and 
vasodilation respectively (Schiffrin, 1995; Deng et al., 1996). Endothelial cell dysfunction is a primary 
pathophysiological complication linked with PE development (Maynard et al., 2003).  
This study demonstrates an upregulation in endothelin-1 concentration in PE compared to normotensive 
pregnancy, irrespective of HIV status. This elevation is attributed to the increased activity of endothelin 
converting enzyme (ECE) found in the circulation of PE (Ajne et al., 2003; Ouellette and Hazelzet, 2011). 
About 60% of circulating ET-1 is removed when the plasma passes through the pulmonary circulation the 
first time which leads to an increase in ET-1 in hypertensive pregnancy (De Nucci et al., 1988). Endothelial 
damage and endotheliosis arising from the imbalance between vasoconstrictor and vasodilator factors may 
increase the levels of ET-1 in circulation leading to PE development (Boura et al., 1994). The increase in 
circulating levels of tumor necrosis factor-α (TNF-α) and the agonistic angiotensin 11 type-1 receptor auto-
antibody (AT1-AA) results in the increase of ET-1 production which leads to maternal hypertension 
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(LaMarca et al., 2011). Moreover, excessive production of ET-1 is linked to pulmonary arterial 
hypertension (PAH) and endothelial dysfunction (Humbert et al., 2004). It is therefore plausible that the 
elevation of ET-1 expression in PE noted in our study may be associated with the widespread endothelial 
dysfunction that characterises PE. However, a study by Mastrogiannis et al., (1991) reported that 
intravenous incorporation of magnesium sulfate significantly decreases ET-1 levels in PE women.  
Based on HIV status, the serum concentration of ET-1 was slightly elevated (non-significant) in HIV 
positive compared to HIV negative participants, regardless of pregnancy type. Mechanisms attributed to 
the increase of ET-1 in the HIV infected population are not clearly expounded. However, chronic 
inflammation from viral infection causes endothelial damage which results in ET-1 production (Mazzuca 
et al., 2018). Notably, viral glycoprotein gp120 stimulates the secretion of ET-1 from endothelial cells 
(Sandoval-Gutierrez et al., 2015). ET-1 production in astrocytes is enhanced by the active viral accessory 
protein Tat (Freeman et al., 2014).  
Importantly, the ET-1 increase noted in our study may be  attributed to the usage of antiretroviral drugs 
such as HAART (Yuhki et al., 2001). Additionally, across all study groups we demonstrate an increase of 
ET-1 in HIV positive PE versus HIV positive normotensive pregnant women. Increased levels in the HIV-
positive PE group are suggestive of the restoration of immune response in PE induced by HAART. 
 
CONCLUSION 
Our study demonstrated the upregulation of ET-1 in PE compared to normotensive pregnant women 
irrespective of HIV status emanating from its powerful vasoconstrictive nature.  This is the first time that 
increased trend of ET-1 albeit non-significant expression in HIV positive compared to HIV negative 
pregnant women has been demonstrated. This elevation was attributed to the increased production of ET-1 
triggered by viral proteins Tat and gp120. It is also plausible that HAART may have influenced ET-1 
expression. Additionally, these results highlight the need for further investigation on the immune 
reconstitution effects of HAART during pregnancy, and the potential of immune inflection therapy for the 
supervision of PE, where treatment remains elusive. 
  
 
 
 
 
 
33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FOUR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
REFERENCES  
 
ACOG, A. C. O. O. A. G. 2019. ACOG Practice Bulletin No. 202: Gestational Hypertension and 
Preeclampsia. Obstetrics & Gynecology. 133, e1-e25. 
AGGARWAL, P., CHANDEL, N., JAIN, V. & JHA, V. J. J. O. H. H. 2012. The relationship between 
circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.  
Journal of human hypertension, 26(4), 236. 
AJNE, G., WOLFF, K., FYHRQUIST, F., CARLSTRÖM, K., HEMSÉN‐MÖRTBERG, A. & NISELL, 
H. J. H. I. P. 2003. Endothelin converting enzyme (ECE) activity in normal pregnancy and 
preeclampsia. Hypertension in pregnancy,  22(3), 215-224. 
AKSORNPHUSITAPHONG, A., PHUPONG, V. J. J. O. O. & RESEARCH, G. 2013. Risk factors of 
early and late onset pre‐eclampsia. Journal of Obstetrics and Gynaecology Research, 39(3), 627-
631. 
ALKEMA, L., CHOU, D., HOGAN, D., ZHANG, S., MOLLER, A.-B., GEMMILL, A., FAT, D. M., 
BOERMA, T., TEMMERMAN, M. & MATHERS, C. J. T. L. 2016. Global, regional, and 
national levels and trends in maternal mortality between 1990 and 2015, with scenario-based 
projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency 
Group.  The Lancet, 387(10017), 462-474. 
APOSTOLOVA, N., BLAS-GARCÍA, A. & ESPLUGUES, J. V. J. T. I. P. S. 2011. Mitochondrial 
interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition. Trends in pharmacological 
sciences, 32(12), 715-725.  
AUNG, M., KONOSHITA, T., MOODLEY, J., GATHIRAM, P. J. E. J. O. O., GYNECOLOGY & 
BIOLOGY, R. 2017. Association of gene polymorphisms of four components of renin-
angiotensin-aldosterone system and preeclampsia in South African black women. European 
Journal of Obstetrics & Gynecology and Reproductive Biology, 215, 180-187. 
BAILEY, H., ZASH, R., RASI, V. & THORNE, C. J. T. L. H. 2018. HIV treatment in pregnancy.  The 
Lancet HIV, 5(8), e457-e467. 
BARNES, K. & TURNER, A. J. J. N. R. 1997. The endothelin system and endothelin-converting enzyme 
in the brain: molecular and cellular studies. Neurochemical research, 22(8), 1033-1040. 
BENNETT, N. J., GILROY, S. & GREENFIELD, R. J. M. H. T. C. Q. Z. 2013. HIV disease. Medscape. 
http://tinyurl. com/75qh8zy (accessed 5 June 2014).  
BERNARDI, F., CONSTANTINO, L., MACHADO, R., PETRONILHO, F., DAL‐PIZZOL, F. J. J. O. O. 
& RESEARCH, G. 2008. Plasma nitric oxide, endothelin‐1, arginase and superoxide dismutase in 
pre‐eclamptic women. Journal of obstetrics and gynaecology research, 34(6), 957-963. 
35 
 
BÖHM, F. & PERNOW, J. J. C. R. 2007. The importance of endothelin-1 for vascular dysfunction in 
cardiovascular disease. Cardiovascular research,  76(1), 8-18. 
BOURA, A., WALTERS, W., READ, M., LEITCH, I. J. C., PHARMACOLOGY, E. & PHYSIOLOGY 
1994. Autacoids and control of human placental blood flow. Clinical and experimental 
pharmacology and physiology,  21(10), 737-748. 
BRIK, A., WONG, C.-H. J. O. & CHEMISTRY, B. 2003. HIV-1 protease: mechanism and drug 
discovery.  Organic & biomolecular chemistry, 1(1), 5-14. 
BROWN, M. A., MAGEE, L. A., KENNY, L. C., KARUMANCHI, S. A., MCCARTHY, F. P., SAITO, 
S., HALL, D. R., WARREN, C. E., ADOYI, G. & ISHAKU, S. J. H. 2018. Hypertensive 
disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for 
international practice. Hypertension, 72(1), 24-43. 
BULL, L., KHAN, A. W., BARTON, S. J. O., GYNAECOLOGY & MEDICINE, R. 2015. Management 
of HIV infection in pregnancy. Obstetrics, Gynaecology & Reproductive Medicine, 25(10), 273-
278. 
CARTY, D. M., DELLES, C. & DOMINICZAK, A. F. J. J. O. H. 2010. Preeclampsia and future maternal 
health. Journal of hypertension, 28(7), 1349-1355. 
CRAICI, I. M., WAGNER, S. J., WEISSGERBER, T. L., GRANDE, J. P. & GAROVIC, V. D. J. K. I. 
2014. Advances in the pathophysiology of pre-eclampsia and related podocyte injury. Kidney 
international,  86(2), 275-285. 
CREASY, R. K. & RESNIK, R. 2004. Maternal-fetal medicine: principles and practice, Gulf 
Professional Publishing. 
D'ORLEANS-JUSTE, P., PLANTE, M., HONORE, J., CARRIER, E., LABONTE, J. J. C. J. O. P. & 
PHARMACOLOGY 2003. Synthesis and degradation of endothelin-1. Canadian journal of 
physiology and pharmacology,  81(6), 503-510. 
DAVENPORT, A. P., HYNDMAN, K. A., DHAUN, N., SOUTHAN, C., KOHAN, D. E., POLLOCK, J. 
S., POLLOCK, D. M., WEBB, D. J. & MAGUIRE, J. J. J. P. R. 2016. 
Endothelin.  Pharmacological reviews, 68(2), 357-418. 
DE NUCCI, G., THOMAS, R., D'ORLEANS-JUSTE, P., ANTUNES, E., WALDER, C., WARNER, T. 
D. & VANE, J. R. J. P. O. T. N. A. O. S. 1988. Pressor effects of circulating endothelin are 
limited by its removal in the pulmonary circulation and by the release of prostacyclin and 
endothelium-derived relaxing factor.  Proceedings of the National Academy of Sciences, 85(24), 
9797-9800. 
36 
 
DECHANET, C., FORT, A., BARBERO-CAMPS, E., DECHAUD, H., RICHARD, S. & VIRSOLVY, 
A. 2011. Endothelin-Dependent Vasoconstriction in Human Uterine Artery: Application to 
Preeclampsia. PLOS ONE, 6(1), e16540. 
DENG, L. Y., DAY, R. & SCHIFFRIN, E. L. J. J. O. T. A. S. O. N. 1996. Localization of sites of 
enhanced expression of endothelin-1 in the kidney of DOCA-salt hypertensive rats. Journal of the 
American Society of Nephrology, 7(8), 1158-1164. 
DESHPANDE, N., JAMES, N., KUCIRKA, L., BOYARSKY, B., GARONZIK‐WANG, J., 
MONTGOMERY, R. & SEGEV, D. J. A. J. O. T. 2011. Pregnancy outcomes in kidney transplant 
recipients: a systematic review and meta‐analysis. American Journal of Transplantation,  11(11), 
2388-2404. 
DIDIER, N., BANKS, W. A., CRÉMINON, C., DEREUDDRE-BOSQUET, N. & MABONDZO, A. J. N. 
2002. HIV-1-induced production of endothelin-1 in an in vitro model of the human blood–brain 
barrier. Neuroreport, 13(9), 1179-1183. 
DUCKITT, K. & HARRINGTON, D. J. B. 2005. Risk factors for pre-eclampsia at antenatal booking: 
systematic review of controlled studies. Bmj, 330(7491), 565. 
ENGLISH, F. A., KENNY, L. C. & MCCARTHY, F. P. J. I. B. P. C. 2015. Risk factors and effective 
management of preeclampsia. Integrated blood pressure control, 8, 7. 
FEIJOO, M. Q., TORO, R., DE LA TORRE, M. L. V., LENNIE, V., ARCE, C., MORENO, V., 
VALENCIA, E., VISPO, E., ALMERÍA, C. & MANGAS, A. J. A. 2014. Relationship between 
endothelin-1 levels and pulmonary arterial hypertension in HIV-infected patients. Aids,  28(18), 
2693-2699. 
FIORE, G., FLORIO, P., MICHELI, L., NENCINI, C., ROSSI, M., CERRETANI, D., AMBROSINI, G., 
GIORGI, G., PETRAGLIA, F. J. T. J. O. C. E. & METABOLISM 2005. Endothelin-1 triggers 
placental oxidative stress pathways: putative role in preeclampsia. The Journal of Clinical 
Endocrinology & Metabolism, 90(7), 4205-4210. 
FREEMAN, B. D., MACHADO, F. S., TANOWITZ, H. B. & DESRUISSEAUX, M. S. J. L. S. 2014. 
Endothelin-1 and its role in the pathogenesis of infectious diseases.  Life sciences, 118(2), 110-
119. 
GATHIRAM, P. & MOODLEY, J. J. C. J. O. A. 2016. Pre-eclampsia: its pathogenesis and 
pathophysiolgy.  Cardiovascular journal of Africa, 27(2), 71. 
GEORGE, E. M. & GRANGER, J. P. 2011. Endothelin: key mediator of hypertension in preeclampsia. 
American journal of hypertension, 24(9), 964-969. 
37 
 
GILBERT, J. S., RYAN, M. J., LAMARCA, B. B., SEDEEK, M., MURPHY, S. R. & GRANGER, J. P. 
2008. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with 
endothelial dysfunction. Am J Physiol Heart Circ Physiol, 294(2), H541-50. 
GRAY, G. A., WEBB, D. J. J. P. & THERAPEUTICS 1996. The endothelin system and its potential as a 
therapeutic target in cardiovascular disease. Pharmacology & therapeutics, 72(2), 109-148. 
HAFFEJEE, F., NAICKER, T., SINGH, M., MOODLEY, J. J. E. J. O. O., GYNECOLOGY & 
BIOLOGY, R. 2013. Placental leptin in HIV-associated preeclampsia. Journal of Obstetrics & 
Gynecology and Reproductive Biology, 171(2), 271-276. 
HALL, D., Gebhardt, S., Theron, G. and Grové, D., 2014. Pre-eclampsia and gestational hypertension are 
less common in HIV infected women. Pregnancy Hypertension: An International Journal of 
Women's Cardiovascular Health, 4(1), pp.91-96.  
HAWFIELD, A. & FREEDMAN, B. I. J. T. A. I. C. D. 2009. Pre-eclampsia: the pivotal role of the 
placenta in its pathophysiology and markers for early detection. Therapeutic advances in 
cardiovascular disease, 3(1), 65-73. 
HEBERT, V. Y., CRENSHAW, B. L., ROMANOFF, R. L., EKSHYYAN, V. P. & DUGAS, T. R. J. C. 
T. 2004. Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. 
Cardiovascular toxicology, 4(2), 117-131. 
HERSE, F. & LAMARCA, B. J. A. J. O. R. I. 2013. Angiotensin II Type 1 Receptor Autoantibody (AT 
1‐AA)‐Mediated Pregnancy Hypertension. American journal of reproductive immunology,  69(4), 
413-418. 
HOD, T., CERDEIRA, A. S. & KARUMANCHI, S. A. J. C. S. H. P. I. M. 2015. Molecular mechanisms 
of preeclampsia. Cold Spring Harbor perspectives in medicine,  5(10), a023473. 
HUMBERT, M., SITBON, O. & SIMONNEAU, G. J. N. E. J. O. M. 2004. Treatment of pulmonary 
arterial hypertension.  New England Journal of Medicine, 351(14), 1425-1436. 
HUMBERT, M. J. A. 2008. Mediators involved in HIV-related pulmonary arterial hypertension. Aids, 22, 
S41-S47. 
IRANI, R. A. & XIA, Y. J. P. 2008. The functional role of the renin–angiotensin system in pregnancy and 
preeclampsia. Placenta, 29(9), 763-771. 
JAIN, A. 2012. Endothelin-1: a key pathological factor in pre-eclampsia? Reprod Biomed Online, 25(5), 
443-9. 
KALUMBA, V., MOODLEY, J. & NAIDOO, T. J. C. J. O. A. 2013. Is the prevalence of pre-eclampsia 
affected by HIV/AIDS? A retrospective case–control study.  Cardiovascular journal of Africa, 
24(2), 24. 
38 
 
KARIM, S. S. A., KARIM, Q. A., GOUWS, E. & BAXTER, C. J. I. D. C. O. N. A. 2007. Global 
epidemiology of HIV-AIDS. Infectious disease clinics of North America, 21(1), 1-17. 
KASSEBAUM, N. J., BERTOZZI-VILLA, A., COGGESHALL, M. S., SHACKELFORD, K. A., 
STEINER, C., HEUTON, K. R., GONZALEZ-MEDINA, D., BARBER, R., HUYNH, C. & 
DICKER, D. J. T. L. 2014. Global, regional, and national levels and causes of maternal mortality 
during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The 
Lancet,  384(9947), 980-1004. 
KAWANABE, Y., NAULI, S. M. J. C. & SCIENCES, M. L. 2011. Endothelin. Cellular and Molecular 
Life Sciences,  68(2), 195-203. 
KHAN, K. S., WOJDYLA, D., SAY, L., GÜLMEZOGLU, A. M. & VAN LOOK, P. F. J. T. L. 2006. 
WHO analysis of causes of maternal death: a systematic review. The lancet, 367(9516), 1066-
1074. 
KHIMJI, A.-K. & ROCKEY, D. C. J. C. S. 2010. Endothelin—biology and disease.  Cellular signalling, 
22(11), 1615-1625. 
KUBLICKIENE, K. R., LINDBLOM, B., KRÜGER, K., NISELL, H. J. A. J. O. O. & GYNECOLOGY 
2000. Preeclampsia: Evidence for impaired shear stress–mediated nitric oxide release in uterine 
circulation. American journal of obstetrics and gynecology, 183(1), 160-166. 
LAM, C., LIM, K.-H. & KARUMANCHI, S. A. J. H. 2005. Circulating angiogenic factors in the 
pathogenesis and prediction of preeclampsia.  Hypertension, 46(5), 1077-1085. 
LAMARCA, B., WALLACE, K. & GRANGER, J. J. C. O. I. P. 2011. Role of angiotensin II type I 
receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Current opinion in pharmacology, 
11(2), 175-179. 
LANDMESSER, U., HORNIG, B. & DREXLER, H. J. C. 2004. Endothelial function: a critical 
determinant in atherosclerosis? Circulation, 109(21), II-27-II-33. 
LEDERMAN, M. M., SERENI, D., SIMONNEAU, G. & VOELKEL, N. F. J. A. 2008. Pulmonary 
arterial hypertension and its association with HIV infection: an overview. Aids, 22, S1-S6. 
LISONKOVA, S., SABR, Y., MAYER, C., YOUNG, C., SKOLL, A., JOSEPH, K. J. O. & 
GYNECOLOGY 2014. Maternal morbidity associated with early-onset and late-onset 
preeclampsia. Obstetrics & Gynecology, 124(4), 771-781. 
LU, Y.-P., HASAN, A. A., ZENG, S., HOCHER, B. J. K. & RESEARCH, B. P. 2017. Plasma ET-1 
concentrations are elevated in pregnant women with hypertension-meta-analysis of clinical 
studies. Kidney and Blood Pressure Research, 42(4), 654-663. 
MAARTENS, G., CELUM, C. & LEWIN, S. R. J. T. L. 2014. HIV infection: epidemiology, 
pathogenesis, treatment, and prevention. The Lancet, 384(9939), 258-271. 
39 
 
MAHARAJ, N. R., PHULUKDAREE, A., NAGIAH, S., RAMKARAN, P., TILOKE, C. & 
CHUTURGOON, A. A. 2017. Pro-Inflammatory Cytokine Levels in HIV Infected and 
Uninfected Pregnant Women with and without Preeclampsia. PLoS One, 12(1), e0170063. 
MALEK, A. & IZUMO, S. J. A. J. O. P.-C. P. 1992. Physiological fluid shear stress causes 
downregulation of endothelin-1 mRNA in bovine aortic endothelium.  American Journal of 
Physiology-Cell Physiology, 263(2), C389-C396. 
MARGARITIS, M. J. A. O. R. H. 2019. Endothelial dysfunction in HIV infection: experimental and 
clinical evidence on the role of oxidative stress. Annals of Research Hospitals, 3. 
MASTROGIANNIS, D. S., O'BRIEN, W. F., KRAMMER, J., BENOIT, R. J. A. J. O. O. & 
GYNECOLOGY 1991. Potential role of endothelin-1 in normal and hypertensive pregnancies. 
American journal of obstetrics and gynecology, 165(6), 1711-1716. 
MATTAR, R., AMED, A. M., LINDSEY, P. C., SASS, N., DAHER, S. J. E. J. O. O., GYNECOLOGY 
& BIOLOGY, R. 2004. Preeclampsia and HIV infection. Obstetrics and Gynecology and 
Reproductive Biology, 117, 240-241. 
MAYNARD, S. E., MIN, J.-Y., MERCHAN, J., LIM, K.-H., LI, J., MONDAL, S., LIBERMANN, T. A., 
MORGAN, J. P., SELLKE, F. W. & STILLMAN, I. E. J. T. J. O. C. I. 2003. Excess placental 
soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, 
hypertension, and proteinuria in preeclampsia. The Journal of clinical investigation, 111(5), 649-
658. 
MAZZUCA, P., CARUSO, A., CACCURI, F. J. E. D. O. C. & CHALLENGES, N. 2018. Endothelial 
Cell Dysfunction in HIV-1 Infection.  Endothelial Dysfunction: Old Concepts and New 
Challenges, 347. 
MCNALLY, R., ALQUDAH, A., OBRADOVIC, D. & MCCLEMENTS, L. J. C. H. R. 2017. Elucidating 
the pathogenesis of pre-eclampsia using in vitro models of spiral uterine artery 
remodelling.  Current hypertension reports, 19(11), 93. 
METTE, S. A., PALEVSKY, H. I., PIETRA, G. G., WILLIAMS, T. M., BRUDER, E., PRESTIPINO, A. 
J., PATRICK, A. & WIRTH, J. A. J. A. R. R. D. 1992. Primary pulmonary hypertension in 
association with human immunodeficiency virus infection. Am Rev Respir Dis, 145, 1196-1200. 
MOGREN, I., HÖGBERG, U., WINKVIST, A. & STENLUND, H. J. E. 1999. Familial occurrence of 
preeclampsia. Epidemiology,518-522. 
MOL, B. W., ROBERTS, C. T., THANGARATINAM, S., MAGEE, L. A., DE GROOT, C. J. & 
HOFMEYR, G. J. J. T. L. 2016. Pre-eclampsia. The Lancet,, 387(10022), 999-1011. 
MOODLEY, J. 2018. Saving Mothers 2014-2016: Seventh triennial report on confidential enquiries into 
maternal deaths in South Africa. 
40 
 
MUKUMBANG, F. C., ORTH, Z., VAN WYK, B. J. H. R. P. & SYSTEMS 2019. What do the 
implementation outcome variables tell us about the scaling-up of the antiretroviral treatment 
adherence clubs in South Africa? A document review. Health research policy and systems, 17(1), 
28. 
NAICKER, T., DORSAMY, E., RAMSURAN, D., BURTON, G. J. & MOODLEY, J. J. H. I. P. 2013. 
The role of apoptosis on trophoblast cell invasion in the placental bed of normotensive and 
preeclamptic pregnancies. Hypertension in pregnancy, 32(3), 245-256. 
NAKIMULI, A., CHAZARA, O., BYAMUGISHA, J., ELLIOTT, A. M., KALEEBU, P., MIREMBE, F., 
MOFFETT, A. J. A. J. O. O. & GYNECOLOGY 2014. Pregnancy, parturition and preeclampsia 
in women of African ancestry. American journal of obstetrics and gynecology, 210(6), 510-520. 
e1. 
NEWELL, M.-L., COOVADIA, H., CORTINA-BORJA, M., ROLLINS, N., GAILLARD, P. & DABIS, 
F. J. T. L. 2004. Mortality of infected and uninfected infants born to HIV-infected mothers in 
Africa: a pooled analysis. The Lancet, 364(9441), 1236-1243. 
NEZAR, M. A.-S., EL-BAKY, A. M. A., SOLIMAN, O. A.-S., ABDEL-HADY, H. A.-S., HAMMAD, 
A. M. & AL-HAGGAR, M. S. J. T. I. J. O. P. 2009. Endothelin-1 and leptin as markers of 
intrauterine growth restriction. The Indian Journal of Pediatrics, 76(5), 485-488. 
NORIS, M., PERICO, N. & REMUZZI, G. J. N. R. N. 2005. Mechanisms of disease: pre-eclampsia.  
Nature Reviews Nephrology, 1(2), 98. 
OUELLETTE, Y. & HAZELZET, J. A. 2011. Endotheliopathy. Pediatric Critical Care. (pp. 1394-1402). 
Elsevier Inc. 
PALEI, A. C., SPRADLEY, F. T., WARRINGTON, J. P., GEORGE, E. M. & GRANGER, J. P. 2013. 
Pathophysiology of Hypertension in Preeclampsia: A Lesson in Integrative Physiology. Acta 
physiologica (Oxford, England), 208(3), 224-233. 
PELAYO, J.C., POOLE, D.P., STEINHOFF, M., C0TRELL, G.S. and BUNNETT, N.W., 2011. 
Endothelin‐converting enzyme‐1 regulates trafficking and signalling of the neurokinin 1 receptor 
in endosomes of myenteric neurones. The Journal of physiology, 589(21), pp.5213-5230.  
PATEL, S., RAUF, A., KHAN, H., ABU-IZNEID, T. J. B. & PHARMACOTHERAPY 2017. Renin-
angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. 
Biomedicine & Pharmacotherapy, 94, 317-325. 
QUEHENBERGER, P., EXNER, M., SUNDER-PLASSMANN, R., RUZICKA, K., BIEGLMAYER, C., 
ENDLER, G., MUELLNER, C., SPEISER, W. & WAGNER, O. J. C. R. 2002. Leptin induces 
endothelin-1 in endothelial cells in vitro. Circulation research, 90(6), 711-718. 
41 
 
RANA, S., LEMOINE, E., GRANGER, J. & KARUMANCHI, S. A. J. C. R. 2019. Preeclampsia: 
pathophysiology, challenges, and perspectives. Circulation research, 124(7), 1094-1112. 
RAYMOND, D., PETERSON, E. J. O. & SURVEY, G. 2011. A critical review of early-onset and late-
onset preeclampsia. Obstetrical & gynecological survey, 66(8), 497-506. 
ROSSI, G. P., SACCHETTO, A., CESARI, M. & PESSINA, A. C. J. C. R. 1999. Interactions between 
endothelin-1 and the renin–angiotensin–aldosterone system. Cardiovascular research, 43(2), 
300-307. 
RUMBOLD, A., DULEY, L., CROWTHER, C. A. & HASLAM, R. R. J. C. D. O. S. R. 2008. 
Antioxidants for preventing pre‐eclampsia. Cochrane database of systematic reviews, (1) 
SALEH, L., DANSER, J. A. & VAN DEN MEIRACKER, A. H. 2016a. Role of endothelin in 
preeclampsia and hypertension following antiangiogenesis treatment. Curr Opin Nephrol 
Hypertens, 25(2), 94-9. 
SALEH, L., VERDONK, K., VISSER, W., VAN DEN MEIRACKER, A. H. & DANSER, A. J. J. T. A. 
I. C. D. 2016b. The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia. 
Therapeutic advances in cardiovascular disease, 10(5), 282-293. 
SANDOVAL-GUTIERREZ, J. L., RODRIGUEZ-SILVERIO, J., RIVERA-ROSALES, R. M., 
SEVILLA-REYES, E., FLORES-MURRIETA, F. J., ROJAS-SERRANO, J. & REYES-TERAN, 
G. J. A. O. M. R. 2015. Overexpression of endothelin-1 leads to more severe pulmonary complex 
vascular lesions associated with the human immunodeficiency virus. Archives of medical 
research, 46(3), 228-232. 
SANSONE, M., SARNO, L., SACCONE, G., BERGHELLA, V., MARUOTTI, G. M., MIGLIUCCI, A., 
CAPONE, A., MARTINELLI, P. J. O. & GYNECOLOGY 2016. Risk of preeclampsia in human 
immunodeficiency virus–infected pregnant women. Obstetrics & Gynecology, 127(6), 1027-
1032. 
SAVING MOTHERS REPORT, N. C. O. C. E. I. M. D. 2015. Saving Mothers 2011-2013: Sixth Report 
on the Confidential Enquiries into Maternal Deaths in South Africa. Short Report. Pretoria: 
NDoH, 2015. 
SAVING MOTHERS REPORT, N. C. O. C. E. I. M. D. J. P. N. D. O. H. 2018. Saving Mothers 2014-
2016: Seventh triennial report on confidential enquiries into maternal deaths in South Africa: 
Executive summary. 
SAVING MOTHERS REPORT, S. A., DNATIONAL DEPARTMENT OF HEALTH 2017. Saving 
Mothers Report 2017. NDoH Pretoria. 
42 
 
SAY, L., CHOU, D., GEMMILL, A., TUNÇALP, Ö., MOLLER, A.-B., DANIELS, J., GÜLMEZOGLU, 
A. M., TEMMERMAN, M. & ALKEMA, L. J. T. L. G. H. 2014. Global causes of maternal 
death: a WHO systematic analysis. The Lancet Global Health, 2(6), e323-e333. 
SCHIFF, E., BEN-BARUCH, G., PELEG, E., ROSENTHAL, T., ALCALAY, M., DEVIR, M., 
MASHIACH, S. J. A. J. O. O. & GYNECOLOGY 1992. Immunoreactive circulating endothelin-
1 in normal andhypertensive pregnancies.  American journal of obstetrics and gynecology, 
166(2), 624-628. 
SCHIFFRIN, E. J. H. 1995. Endothelin: potential role in hypertension and vascular hypertrophy. 
Hypertension, 25(6), 1135-1143. 
SHANGE, G. P., MOODLEY, J. & NAICKER, T. 2017. Effect of vascular endothelial growth factors A, 
C, and D in HIV-associated pre-eclampsia. Hypertens Pregnancy, 36(2), 196-203. 
SIDDIQUI, I. A., JALEEL, A., TAMIMI, W., AL KADRI, H. M. J. A. O. G. & OBSTETRICS 2010. 
Role of oxidative stress in the pathogenesis of preeclampsia. Archives of gynecology and 
obstetrics, 282(5), 469-474. 
SIMBAYI, L., ZUMA, K., ZUNGU, N., MOYO, S., MARINDA, E., JOOSTE, S., MABASO, M., 
RAMLAGAN, S., NORTH, A. & VAN ZYL, J. 2019. South African National HIV Prevalence, 
Incidence, Behaviour and Communication Survey, 2017: towards achieving the UNAIDS 90-90-
90 targets. 
Statistics South Africa. Mid-year population estimates 2018. 2019;(July).  
SUY, A., MARTÍNEZ, E., COLL, O., LONCA, M., PALACIO, M., DE LAZZARI, E., LARROUSSE, 
M., MILINKOVIC, A., HERNÁNDEZ, S. & BLANCO, J. L. J. A. 2006. Increased risk of pre-
eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral 
therapy. Aids, 20(1), 59-66. 
TAKAHASHI, M., FUKUDA, K., SHIMADA, K., BARNES, K., TURNER, A., IKEDA, M., KOIKE, 
H., YAMAMOTO, Y. & TANZAWA, K. J. B. J. 1995. Localization of rat endothelin-converting 
enzyme to vascular endothelial cells and some secretory cells. Biochemical Journal, 311(2), 657-
665. 
TANNETTA, D., MASLIUKAITE, I., VATISH, M., REDMAN, C. & SARGENT, I. J. J. O. R. I. 2017. 
Update of syncytiotrophoblast derived extracellular vesicles in normal pregnancy and 
preeclampsia. Journal of reproductive immunology, 119, 98-106. 
TAYLOR, R. N., VARMA, M., TENG, N. N., ROBERTS, J. M. J. T. J. O. C. E. & METABOLISM 
1990. Women with preeclampsia have higher plasma endothelin levels than women with normal 
pregnancies. The Journal of Clinical Endocrinology & Metabolism, 71(6), 1675-1677. 
UNAIDS, J. U. N. P. O. H. A. 2015. The gap report. Geneva: UNAIDS; 2014. 
43 
 
UNAIDS, U. N. P. O. H. A. 2018. UNAIDS data 2017. Recuperado de: http://www. unaids. 
org/sites/default/files/media_asset …. 
VERMA, S., PILLAY, P., NAICKER, T., MOODLEY, J., MACKRAJ, I. J. E. J. O. O., GYNECOLOGY 
& BIOLOGY, R. 2018. Placental hypoxia inducible factor-1α & CHOP immuno-histochemical 
expression relative to maternal circulatory syncytiotrophoblast micro-vesicles in preeclamptic and 
normotensive pregnancies. European Journal of Obstetrics & Gynecology and Reproductive 
Biology, 220, 18-24. 
VIDYA VIJAYAN, K., KARTHIGEYAN, K. P., TRIPATHI, S. P. & HANNA, L. E. J. F. I. I. 2017. 
Pathophysiology of CD4+ T-cell depletion in HIV-1 and HIV-2 infections.  Frontiers in 
immunology, 8, 580. 
WALSH, S. W. J. T. I. E. M. 2007. Obesity: a risk factor for preeclampsia. Trends in Endocrinology & 
Metabolism, 18(10), 365-370. 
WANG, A., RANA, S. & KARUMANCHI, S. A. J. P. 2009. Preeclampsia: the role of angiogenic factors 
in its pathogenesis. Physiology, 24(3), 147-158. 
WHO, W. H. O. 2015. Strategies towards ending preventable maternal mortality (EPMM). 
WHO, W. H. O. 2016a. Consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection: recommendations for a public health approach, World Health 
Organization. 
WHO, W. H. O. 2016b. WHO recommendations for prevention and treatment of pre-eclampsia and 
eclampsia. Geneva: World Health Organization; 2011. 
WHO, W. H. O., UNICEF 2014. Trends in maternal mortality: 1990 to 2013: estimates by WHO, 
UNICEF, UNFPA, The World Bank and the United Nations Population Division. 
WOLDESENBET, S., KUFA, T., LOMBARD, C., MANDA, S., AYALEW, K., CHEYIP, M. & 
PUREN, A. 2017. KEY FINDINGS OF THE 2017 SOUTH AFRICAN ANTENATAL HIV 
SENTINEL SURVEY (ANCHSS). 
WOLFF, K., NISELL, H., CARLSTRÖM, K., KUBLICKIENE, K., HEMSÉN, A., LUNELL, N.-O. & 
LINDBLOM, B. J. R. P. 1996. Endothelin-1 and big endothelin-1 levels in normal term 
pregnancy and in preeclampsia. Regulatory peptides, 67(3), 211-216. 
YANAGISAWA, M., KURIHARA, H., KIMURA, S., TOMOBE, Y., KOBAYASHI, M., MITSUI, Y., 
YAZAKI, Y., GOTO, K. & MASAKI, T. J. N. 1988. A novel potent vasoconstrictor peptide 
produced by vascular endothelial cells. nature, 332(6163), 411. 
YUHKI, K.-I., MIYAUCHI, T., KAKINUMA, Y., MURAKOSHI, N., MAEDA, S., GOTO, K., 
YAMAGUCHI, I. & SUZUKI, T. J. J. O. C. P. 2001. Endothelin-1 production is enhanced by 
44 
 
rotenone, a mitochondrial complex I inhibitor, in cultured rat cardiomyocytes. Journal of 
cardiovascular pharmacology, 38(6), 850-858. 
ZHOU, C. C., IRANI, R. A., DAI, Y., BLACKWELL, S. C., HICKS, M. J., RAMIN, S. M., KELLEMS, 
R. E. & XIA, Y. J. T. J. O. I. 2011. Autoantibody-mediated IL-6–dependent endothelin-1 
elevation underlies pathogenesis in a mouse model of preeclampsia. The Journal of Immunology, 
186(10), 6024-6034. 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FIVE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
 
APPENDICES 
 
 
